70 million market cap for AGN back in 2023 for “encouraging pre clinical results” compared to NYR 15 million market cap which already has “significant” and “strong efficacy”. Results for NYR were significantly stronger in stroke and Walter reed for traumatic brain injury that starts in April put NYR on the path to a 100 million dollar market cap at a 80 cents target price short term. Interesting times ahead
